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Abstract - Gene polymorphisms result from evolutionary processes representing mutations that survive in the population 
with a frequency higher than 1%. The most investigated type of gene polymorphisms are single nucleotide polymorphisms 
(SNPs). The SNPs of IL-12B (rs 3212227) A/C among a population of kidney graft CMV-seropositive recipients have an 
impact on a clinical events in cytomegalovirus (CMV) disease. Constitutive -308 G/A TNF-α polymorphism (rs1800629) 
is related to the susceptibility of HR-HPV-associated cervical dysplasia and cancer. SNP located 3 kb upstream of the IL-
28B gene (rs12979860) seems to be the strongest host genetic predictor of sustained virologic response (SVR) in hepatitis 
C genotype 1 patients. It is very important to identify viral and host genetic markers that may facilitate the risk of devel-
oping viral disease or some viral-associated cancers. In addition, these markers could be useful in the choice of effective 
treatments and preventive strategies against virally induced infection.
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Gene  polymorphisms  are  the  result  of  evolution-
ary  processes  representing  mutations  that  survive 
in the population with a frequency higher than 1% 
(Attia et al., 2009). Within the human genome DNA 
polymorphisms occur every couple of hundred base 
pairs. The most investigated type of gene polymor-
phisms are single nucleotide polymorphisms (SNPs) 
represented by substitution, insertion or deletion of 
a single DNA base. The functionality of each SNP de-
pends on its position in the gene, the most relevant 
ones being those in regulatory regions of the gene. 
Polymorphisms located in 5’ promoter/enhancer of 
the gene can control the level of gene transcription, 
exon polymorphisms often change the DNA coding 
sequence, polymorphisms in introns may affect dif-
ferential RNA splicing, while polymorphisms in the 
3’ UTR region can influence mRNA stability. There 
are an estimated 1.42 million SNPs in the human ge-
nome. Because of this, a reliable nomenclature with 
a reference sequence (rs) number for each SNP is re-
quired (Goldstein, 2009).
Recently,  in  order  to  define  useful  disease  bi-
omarkers, many immunogenetic and pharmacoge-
netic investigations have been performed worldwide. 
Biomarkers are biological characteristics that can be 
detected and measured, such as genes, gene products 
and various other molecules. It is essential to dis-
tinguish  between  disease-related  and  drug-related 
biomarkers. Disease-related biomarkers can be diag-
nostic biomarkers, if a disease already exists, or can 
suggest how a disease may develop in an individual 596 MAJA ĆUPIĆ ET AL.
case (prognostic biomarker). Drug-related biomark-
ers indicate whether a drug will be effective in a cer-
tain patient and how the patient’s body will process 
it. Genomic biomarkers have an important place in 
the  development  of  novel  clinical  and  therapeutic 
approaches in patients with viral diseases, especially 
those that are on immunosuppressive therapy (Hir-
schhorn et al., 2005).
Recently, many reports in the literature have de-
scribed the role of certain cytokine gene polymor-
phisms in the development of viral diseases, efficacy 
of antiviral therapy and even in the risk of develop-
ing tumors of viral origin.
Association between a polymorphism in the IL-12B 
gene and cytomegalovirus reactivation in kidney 
transplant recipients
Cytomegalovirus (CMV) infection remains one 
of  the  most  frequent  infection  disease  after  renal 
transplantation,  with  an  incidence  in  the  kidney 
transplant population estimated to be between 8 and 
32% (Hartmann et al., 2006). This herpes virus in-
fects mostly adults and remains latent throughout 
life.  CMV  infection  in  transplant  recipients  is  di-
rectly associated with a significant rate of morbidity 
and its indirect effects on transplant recipients have 
been  increasingly  recognized  during  recent  year 
(Brennan,  2001).  After  transplantation,  a  number 
of donor-derived proteins are recognized as foreign 
antigens by the recipient’s immune system, resulting 
in acute rejection whereby grafted cells are rapidly 
and specifically eliminated by the recipient immune 
system. Immunosuppressive drugs are used to pre-
vent this reaction, but at the same time, these treat-
ments are generally associated with an increased risk 
of many infections. In response to these infections, 
the host usually mobilizes both innate and adaptive 
immunity to ensure appropriate control of the infec-
tion. Innate immunity plays a crucial role in limit-
ing early viral replication through the activation of 
natural  killer  (NK)  cells  and  interferon-γ  (IFN-γ) 
production (Segedal et al., 2004). Specific immunity 
is mainly mediated by T lymphocytes, CD8+ T cells 
being primarily responsible for the viral clearance in 
peripheral organs (Lucin et al., 1992; Halary et al., 
2005). Gamma delta T cells also participate in the 
early immune response to CMV, possibly through 
IFN-γ synthesis (Lafarge et al., 2001). 
The T cell-mediated immune response is regulat-
ed through an intricate network of molecular signals, 
including interleukin-12 (IL-12) which directs T cell 
response towards Th1 differentiation and stimulates 
IFN-γ production in T and NK cells, acting as a ma-
jor player in the balance between Th1- and Th2-type 
immune responses. IL-12p70, mainly produced by 
macrophages and dendritic cells (DC) after encoun-
tering the antigens, is composed of two subunits: p35 
and p40 encoded by IL-12A and IL-12B genes located 
on two different chromosomes. An SNP in the 3’un-
translated  region  (3’UTR)  of  IL-12B  (rs  3212227) 
is  represented  by  A  to  C  substitution  at  position 
+1188 in the mRNA, reducing the stability of the p40 
mRNA, which results in the decrease of IL-12 p40 
production by stimulated peripheral blood mono-
cyte  cells  (PBMCs)  (Stanilova  and  Miteva,  2005). 
This SNP appears to be clinically relevant in suscep-
tibility to multiple sclerosis and psoriasis vulgaris, 
but in recent years it has also been described as a risk 
factor for the occurrence of CMV infection after kid-
ney transplantation. Distribution of the genotypes 
of this IL-12B 3’UTR polymorphism in kidney-graft 
CMV-seropositive patients is reported to be 60% for 
AA genotype, 36% are AC heterozygotes, while CC 
genotype is present in 4% patients (Hoffmann et al., 
2008). This distribution is in Hardy-Weinberg equi-
librium, which indicates that its genetic diversity was 
stable. The C allele frequency is 22% and it is strong-
ly associated with lower mRNA stability and lower 
production of the p40 protein (van Veen et al., 2001; 
Hoffman et al., 2009). Lower p40 expression in the C 
carriers might explain the pathogenic link between 
the  IL-12B  genotype  and  CMV  replication.  IL-12 
p40 directly stimulates IFN-γ production by CD8+T 
cells and both cytotoxic T cells and IFN-γ represent 
major mediators in the host defense against CMV. 
This suggests that the level of p40 expression may 
play an important role during CMV infection. IL-
12B polymorphism (rs 3212227) in a population of 
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an impact on the clinical course of the CMV disease. 
Therefore, the patients who are C allele carriers might 
greatly benefit from CMV prophylaxis, which should 
be administrated immediately after transplantation 
to all patients with a risk of CMV disease. 
Association of TNF-α gene promoter polymorphism 
in HPV-associated cervical cancer
Another genetic biomarker related to the associa-
tion with viral infection is tumor necrosis factor-α 
(TNF-α) and its gene that has been described in cor-
relation with susceptibility to HPV-associated cer-
vical dysplasia and cancer (Muñoz, 2000). Cervical 
cancer is the most common genital malignancy that 
has  high  morbidity  and  mortality  among  women 
around the world, especially in developing countries 
(Waggoner, 2003). Infection with high-risk human 
papillomavirus (HR-HPV) is an important factor in 
the development of this cancer. Persistent HR-HPV 
infection induces an inflammatory response and cy-
tokines that play an important role in this process 
can influence the development of the disease (Gaiotti 
et al., 2000; Govan et al., 2006). A pronounced shift 
from a Th1 (pro-inflammatory) cytokine production 
to a Th2 (anti-inflammatory) cytokine production 
has been observed in contrast-induced necropathy 
(CIN) patients with extensive HPV infection (Jang 
et al., 2001), suggesting that the type of cytokine re-
sponse in HPV infection may be influential in de-
termining  disease  outcome.  In  addition,  there  is 
evidence that reduced Th1 cytokine levels and in-
creased Th2 levels (Bais et al., 2005) are associated 
with poor prognosis in cervical cancer (Kirkpatrick 
et al., 2004). 
TNF-α,  a  pro-inflammatory  cytokine,  plays  a 
pivotal role in the pathogenesis of a variety of infec-
tious and inflammatory diseases (Field, 2001). Previ-
ous reports indicated that TNF-α promotes the pro-
gression of cell cycle by increasing cyclin-dependent 
kinase activity and HPV16 E6/E7 mRNA expression 
in  HPV-immortalized  keratinocytes  (Szlosarek  et 
al., 2006). In addition, it has been shown that TNF-α 
enhances the transcription and stability of the epi-
dermal  growth  factor  receptor  (EGFR),  resulting 
in cell proliferation and tumorigenesis. Recently, it 
has been reported that the level of serum TNF-α in 
women with CIN was much higher than in healthy 
controls (Mocellin et al., 2005; Akkiz et al., 2009). In 
HPV-associated CIN, individual cytokine gene poly-
morphisms might potentially affect the disease proc-
ess through several mechanisms, including the mod-
eration of cytokine production in response to HPV. 
Single base polymorphism at the position -308 in the 
promoter of the TNF-α gene (rs1800629), represent-
ed by G to A substitution, is biologically very impor-
tant. Its increased in vitro and in vivo transcription 
by 6- to 9-fold may affect susceptibility to cervical 
cancer (Stanczuk et al., 2003). This SNP can influ-
ence the expression of TNF-α, with the less common 
-308 A allele resulting in higher TNF-α production, 
and relates to a 2-fold increase in the risk of invasive 
cervical cancer. In contrast, the -308 G allele is linked 
to the reduced TNF-α production and low risk in 
HPV-associated  cervical  dysplasia  (Kirkpatrick  et 
al., 2004). Indeed, these observations presented the 
possibility that tumor development may be associ-
ated with the genetic predisposition of the host to 
produce higher levels of TNF-α (Deshpande et al., 
2005). Numerous studies have investigated the asso-
ciation between the effect of TNF-α promoter region 
variations and cervical cancer, but the results have 
been contradictory (Calhoun et al., 2002). Notably, 
these findings are from various ethnic populations, 
indicating that the variation in TNF-α production 
may be influenced by the genetic make-up of ethni-
cally diverse populations, contributing to the dispar-
ity in disease outcome (Ghaderi et al., 2001; Zuo et 
al., 2011).
Association of IL-28B polymorphism and response to 
therapy in hepatitis C patients
Hepatitis C infection is a major global public health 
problem. Among individuals infected with hepatitis 
C virus (HCV), approximately 80% develop chron-
ic HCV infection. Chronic infection is the leading 
cause of liver cancer worldwide (Alavian, 2011). Suc-
cessful treatment of chronic HCV infection results 
in a sustained virologic response (SVR), observed as 
undetectable post-treatment HCV RNA in the plas-598 MAJA ĆUPIĆ ET AL.
ma that greatly reduces the risk of cirrhosis and liver 
cancer.  Current  treatment  for  patients  chronically 
infected  with  genotype  1  HCV  requires  48  weeks 
of  pegylated  interferon  (PEG  IFN)  plus  Ribavirin 
(RBV) (Tanaka et al., 2009). The goal of this treat-
ment is viral eradication, defined as the absence of 
virus 24 weeks after treatment completion, but it is 
usually achieved only in <50% of patients. Treatment 
of HCV infection with PEG IFN-α plus RBV, as a 
standard of care for the management of this disease, 
leads to the eradication of the virus in less than 60% 
of patients (Hoofnagle and Seeff, 2006).
Genome-wide association study (GWAS) found 
the SNP present 3 kb upstream of the IL-28B gene 
(rs12979860) to be the strongest host genetic predic-
tor of SVR in HCV genotype 1 (Tanaka et al., 2009). 
IL-28B is located on chromosome 19 and it encodes 
a  protein  also  known  as  IFN-λ3.  In  vitro  studies 
have suggested that IFN-α induces the expression of 
interferon-λ genes (Maher et al., 2008) and that IFN-λ 
inhibits HCV replication through a pattern of signal 
transduction and regulation of interferon-stimulated 
genes, which is distinct from that of IFN-α. IFN-α 
and IFN-λ proteins both induce The Janus-activated 
kinase (JAK) and the signal transducer and activator 
of transcriptions (STAT) pathway upregulates sev-
eral hundred interferon-stimulated genes. Through 
this mechanism IFN-α and IFN-λ suppress viral in-
fections (Muir et al., 2010). .
There are three IL-28B genotypes: CC, CT, and 
TT. Patients with the CC genotype have a stronger 
immune response to HCV infection than individu-
als with CT or TT genotypes (called non-CC geno-
types). A stronger immune response most probably 
enables patients who have a CC genotype to clear the 
HCV within months of becoming infected without 
treatment. Patients with CC genotype are also 2 to 3 
times more likely to be cured by PEG-IFN and RBV. 
Hence, two of the strongest SVR predictors are the 
virus-related  amount  of  HCV  in  the  bloodstream 
(HCV-viral load) and the HCV genotype (Thomp-
son et al., 2010). Based on all the above-mentioned, 
genotyping of this polymorphism could aid clinical 
decision in defining the standard of care for these pa-
tients and providing an opportunity for clinicians to 
individualize treatment regimens for HCV patients.
In the light of all that has been discussed, it is very 
important to identify viral and host genetic markers 
that may facilitate the risk of developing viral disease 
or some viral-associated cancers. In addition, these 
markers could be useful in providing options for ef-
fective treatments and preventive strategies against 
virally induced infection.
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